Christopher R. Fenimore - 06 Dec 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
SVP Finance & CFO
Signature
/s/ Christopher R. Fenimore
Issuer symbol
REGN
Transactions as of
06 Dec 2024
Net transactions value
-$897,180
Form type
4
Filing time
10 Dec 2024, 16:03:32 UTC
Previous filing
29 Aug 2024
Next filing
18 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Award $0 +2,591 +17% $0.000000 17,896 06 Dec 2024 Direct F1
transaction REGN Common Stock Tax liability $897,180 -1,140 -6.4% $787.00 16,756 09 Dec 2024 Direct
holding REGN Common Stock 1,515 06 Dec 2024 By 401(k) Plan
holding REGN Common Stock 1,897 06 Dec 2024 By Trust F2
holding REGN Common Stock 25 06 Dec 2024 by Trust for Daugh
holding REGN Common Stock 25 06 Dec 2024 by Trust for Son

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Award $0 +9,979 $0.000000 9,979 06 Dec 2024 Common Stock 9,979 $771.64 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 6, 2026 and 50% on December 6, 2028.
F2 These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
F3 The stock option award vests in four equal annual installments, commencing one year after the date of grant.